| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
• AC Immune, Inc. (NASDAQ:ACIU) shares rose 88.45% to $13.55 during Thursday's pre-market session.
• Nabriva Therapeutics, Inc. (NASDAQ:NBRV) stock increased by 62.40% to $1.08.
• Lannett, Inc. (NYSE:LCI) shares increased by 28.27% to $6.60.
• Tiziana Life Sciences, Inc. (NASDAQ:TLSA) shares rose 10.42% to $9.53.
• Intec Pharma, Inc. (NASDAQ:NTEC) shares moved upwards by 9.39% to $0.34.
• Veru, Inc. (NASDAQ:VERU) shares increased by 7.66% to $3.37. The most recent rating by Oppenheimer, on May 14, is at Outperform, with a price target of $9.
• Adamis Pharmaceuticals, Inc. (NASDAQ:ADMP) shares increased by 6.47% to $0.70. The most recent rating by Maxim Group, on May 13, is at Buy, with a price target of $2.
• NextCure, Inc. (NASDAQ:NXTC) shares moved upwards by 5.10% to $9.47. The most recent rating by Benchmark, on Jul 16, is at Buy, with a price target of $17.
• Enzo Biochem, Inc. (NYSE:ENZ) shares rose 4.39% to $2.61.
• BioNTech, Inc. (NASDAQ:BNTX) stock increased by 3.97% to $81.10. The most recent rating by Canaccord Genuity, on Jul 13, is at Buy, with a price target of $75.
• Tricida, Inc. (NASDAQ:TCDA) stock decreased by 33.63% to $17.39 during Thursday's pre-market session.
• INmune Bio, Inc. (NASDAQ:INMB) stock fell 16.48% to $10.90. The most recent rating by HC Wainwright & Co., on Jul 15, is at Buy, with a price target of $20.
• Lianluo Smart, Inc. (NASDAQ:LLIT) stock decreased by 12.40% to $0.52.
• Aptose Biosciences, Inc. (NASDAQ:APTO) stock fell 11.83% to $5.52.
• VIVUS, Inc. (NASDAQ:VVUS) stock decreased by 9.31% to $0.47.
• Genetic Technologies, Inc. (NASDAQ:GENE) stock decreased by 8.29% to $5.20.
• Immutep, Inc. (NASDAQ:IMMP) stock declined 8.22% to $1.34.
• Ocugen, Inc. (NASDAQ:OCGN) shares declined 6.63% to $0.20. The most recent rating by Chardan Capital, on Jun 3, is at Buy, with a price target of $1.
• Equillium, Inc. (NASDAQ:EQ) shares declined 6.24% to $16.25. The most recent rating by HC Wainwright & Co., on Jul 14, is at Buy, with a price target of $24.
• Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shares declined 5.49% to $3.10. The most recent rating by JP Morgan, on May 27, is at Overweight, with a price target of $6.
Posted In: ACIU ADMP APTO BNTX ENZ EQ GENE IMMP INMB LCI LLIT NBRV NTEC NXTC OCGN RIGL TCDA TLSA VERU VVUS
